Curia Hybridoma Discovery Workflow

In vivo Hybridoma Approach to Identify Novel Therapeutic- and Diagnostic-Grade Antibodies

The Curia hybridoma platform offers a variety of high-performance hybridoma technologies to discover great antibodies. The specific discovery approach depends on project-intrinsic parameters. These comprise practical (client resource, timeline) and scientific considerations. For the latter, we perform a rigorous upfront target analysis to devise the best discovery approach.  Here we use bioinformatics, literature, and patent data to identify target-specific considerations that could impact our discovery efforts. This due diligence helps ensure that we are following an optimal path for antibody discovery from the outset.

View our latest hydrodynamic gene transfer (HDT) publications related to DNA-based immunization:

Robust Expansion of Dendritic Cells in vivo by Hydrodynamic FLT3L-FC Gene Transfer

A Chimeric Antibody Against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models


Hybridoma Discovery Workflow at Curia

Other differentiators:

  • Multiple immunization strategies (protein, DNA, cell-based immunogens) using a variety of WT strains and/or human-antibody producing transgenics and/or target-specific KOs coupled with in-life plasma titer checks allows us to track antibody responses in vivo and focus on the most promising animals for subsequent fusion and antibody recovery.
  • Expertise in innovative tolerance-breaking approaches for targets with high human-mouse identity or if human/mouse target cross-reactivity is required.
  • 384-well screening format enables high capacity enables interrogation of 4,000-12,000 hybridomas in a standard campaign.
  • Intellicyt® iQue Screeners enable high-throughput multiplex flow cytometry-based primary screening to immediately identify hits with desired specificity and cross-reactivity requirements.
  • Functional assay development and integration into screening cascade
  • Seamless integration with Curia’s complete range of analytic and production capabilities (immunogen production, cell line generation, hybridoma sequencing, purified antibody production, affinity measurements by Carterra® (SPR) and Octet®, recombinant production at any desired scale, humanization/affinity maturation if needed)

Campaign Customization Options

Immunogen Options
Curia can custom design and prepare antigens based on client needs.

Binding and Functional Assays
Curia can customize epitope binning, blocking, internalization, ADCC assays, and more.

Wildtype and fully human transgenic mouse strains are available. If special strains are needed, Curia can introduce animal vendors within the Curia Antibody Technology Network.

A variety of immunizations are available to suit each client’s project goals and timelines.
• Tolerance-breaking approaches can achieve titer against mouse targets and increase epitope diversity.
• Proprietary DNA immunogen and UberCell™ approaches can lead to high titers against challenging transmembrane targets such as GPCRs.
• Rapid protein-based approaches such as RIMMS7™ and HT-HOCK™ can achieve high titer within a short time frame.

Immunization Comparisons

Curia’s Due Diligence

To increase the probability of campaign success, Curia conducts rigorous target analysis utilizing bioinformatics, literature, and patent data to identify target-specific considerations that could impact discovery effort. Throughout the campaign, clients will receive data updates, allowing the tracking of hybridomas from immunization to sequence.

Hybridoma Campaigns by the Number

completed discovery campaigns
hit identification success rate
clients served